Severity, not anxiety
Every therapeutic peptide has side effects. Pretending otherwise is malpractice. The goal of patient education is not to alarm — it is to make sure the patient recognizes the difference between a transient adjustment, a manageable side effect, and a stop-and-call-the-doctor event.
We rate side effects on a three-tier scale: common and transient; manageable with dose adjustment; serious — discontinue immediately.
| Severity | Examples | Action |
|---|---|---|
| Common | Injection-site redness, mild nausea, headache | Monitor; usually resolves in 1-2 weeks |
| Manageable | Persistent nausea, fluid retention, fatigue | Contact physician; dose titration likely |
| Serious | Severe abdominal pain, vision changes, allergic reaction | Stop immediately; seek urgent care |
GLP-1 class (semaglutide, tirzepatide)
The most common adverse events are gastrointestinal: nausea, constipation, occasional vomiting, especially during titration. These typically resolve within four to six weeks. Persistent severe abdominal pain is not normal and warrants evaluation for pancreatitis or gallbladder pathology.
Rare but documented: thyroid C-cell tumors (in rodent models — human signal unclear), acute kidney injury from dehydration, retinopathy progression in patients with established diabetic retinopathy.
Growth-hormone-axis peptides (CJC-1295, ipamorelin, sermorelin)
Mild water retention, transient injection-site reactions, occasional carpal-tunnel-like paresthesias at higher doses. Insulin sensitivity can decrease slightly during active GH-axis modulation — relevant for prediabetic patients.
Do not stack multiple GH-axis peptides without clinical supervision. The IGF-1 ceiling is a real safety margin; the goal is restoration, not supraphysiology.
Share
References
- [1]Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Link